Previous Article | Next Article 
Journal of Clinical Microbiology, June 2007, p. 2020-2024, Vol. 45, No. 6
0095-1137/07/$08.00+0 doi:10.1128/JCM.02591-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Subtyping Method for Escherichia coli Shiga Toxin (Verocytotoxin) 2 Variants and Correlations to Clinical Manifestations
Søren Persson,1*
Katharina E. P. Olsen,1
Steen Ethelberg,1 and
Flemming Scheutz1,2
Department of Bacteriology, Mycology and Parasitology, Unit of Gastrointestinal Infections, Statens Serum Institut, Copenhagen, Denmark,1
The International Escherichia and Klebsiella Centre (WHO), Unit of Gastrointestinal Infections, Statens Serum Institut, Copenhagen, Denmark2
Received 27 December 2006/
Returned for modification 27 January 2007/
Accepted 4 April 2007

ABSTRACT
Shiga toxin 2 (Stx2) from Shiga toxin-producing
Escherichia coli (STEC) was subtyped by a method involving partial sequencing
of the
stxAB2 operon. Of 255 strains from the Danish STEC cohort,
all 20 cases of hemolytic-uremic syndrome were associated with
subtype Stx2 (11 cases), subtype Stx2c (1 case), or the two
combined (8 cases).

TEXT
Infections caused by Shiga toxin-producing
Escherichia coli (STEC), alternatively known as verocytotoxin-producing
E. coli,
account for the most severe symptoms among those caused by diarrheagenic
E. coli, sometimes leading to bloody diarrhea (BD) or hemolytic-uremic
syndrome (HUS). STEC is defined by the ability to produce Shiga
toxins (Stx or verocytotoxin) 1 and 2, which are two sequentially
and antigenetically distinct toxin groups transcribed from the
stxAB1 and
stxAB2 operons, respectively. Besides the
stx gene(s),
STEC strains often carry the gene encoding the adherence factor
intimin (
eae), which is an outer membrane protein (
14). It has
previously been shown that there exists an increased risk for
developing HUS when both
stx2 and
eae are present in the infecting
strain (
4,
7,
11). Additionally, a number of studies have documented
that subtypes
stx2 and
stx2c are more often associated with
HUS than the other
stx2 subtypes (
5,
6,
8,
15), but
stx2d (
9,
13,
16)- and
stx2e (
11)-containing strains have also been isolated
from humans with HUS. PCR-restriction fragment length polymorphism
has often been the preferred tool for subtyping
stx2 variants
(
2,
3,
5,
6,
8,
10,
17-
19,
22). These methods are, however,
vulnerable to single-nucleotide changes and are difficult to
interpret if the strain contains more than one subtype or if
the fragments generated are small or of similar sizes. For a
new and improved subtyping method for the Stx2 toxin, we applied
partial sequencing of the most variable part of the
stxAB2 operon.
By applying this method to the
stx2-positive isolates from the
Danish National STEC cohort from 1997 to 2003, we hoped to clarify
the epidemiology of human
stx2 subtypes and to correlate specific
subtypes with clinical manifestations of BD and HUS.
(The results of this study were presented in part at the 14th European Congress of Clinical Microbiology and Infectious Diseases [ECCMID], Prague, Czech Republic, May 2004 [poster no. P972], and at the 2nd Met-Vet-Net Meeting, Qawra, Malta, May 2006 [poster no. HMI&ME23]).
All clinical STEC strains included in this study were characterized at the Unit of Gastrointestinal Infections, Statens Serum Institut (SSI), Denmark. About 90% of the strains were isolated at the SSI from individuals suffering from diarrhea, using DNA dot blot hybridization with broad-range polynucleotide DNA probes derived from plasmids pNTP705 for stx1 (23), pDEP28 for stx2 (21), and pCVD434 for eae (12). The remaining STEC strains originated either from patients with diarrhea who had stool cultures analyzed for the most common STEC O groups (at regional clinical laboratories) or from asymptomatic carriers analyzed because of close contact to STEC-infected individuals. The data set consists of 44 different O groups and is presumably not biased toward certain O groups; there were no general outbreaks within the study period. Retrieval of patient information concerning the illness was performed throughout the study period by patient interviews as described previously (7). STEC strains were grown on agar plates under standard conditions and prepared for PCR in the following way. One colony was transferred to 100 µl 10% Chelex 100 (Bio-Rad, Hercules) in 10 mM Tris-HCl, 1 mM EDTA, pH 8, boiled for 5 min, and centrifuged briefly. The supernatant was used directly for PCR. Each template was subjected to PCR with the following primers: F4, 5'-GGCACTGTCTGAAACTGCTCCTGT (matched all subtypes except stx2f); R1, 5'-ATTAAACTGCACTTCAGCAAATCC (matched all subtypes except stx2e and stx2f); F4-f, 5'-CGCTGTCTGAGGCATCTCCGCT (matched stx2f); and R1-e/f, 5'-TAAACTTCACCTGGGCAAAGCC (matched stx2e and stx2f). PCRs were carried out in a total reaction volume of 25 µl containing 1x PCR buffer [50 mM Tris-HCl, 10 mM KCl, 5 mM (NH4)2SO4, pH 8.3], 2.6 mM MgCl2, 260 µM of each deoxynucleoside triphosphate, 1.25 U Taq polymerase (FastStart, Roche Diagnostics GmbH, Mannheim, Germany), 0.05 µM of each of the four primers, and 5 µl template. The thermocycler conditions were as follows: 95°C for 2 min, followed by 35 cycles of 94°C for 50 s, 58°C for 40 s, and 72°C for 50 s, and finally 72°C for 3 min. The completed PCR products were purified by a QIAquick PCR purification kit (QIAGEN, Hilden, Germany) and sequenced at MWG-BIOTECH AG, Ebersberg, Germany. If the first sequencing attempt using primer F4 or R1 failed, amplicons were sequenced with primer F4-f or R1-e/f. Sequencing with forward and reverse PCR primers generated a 491-bp internal high-quality sequence on the approximately 620-bp PCR product. The nucleotide sequence was translated into 159 amino acids, covering 95 residues of the C-terminal part of subunit A and 64 residues of the N-terminal part of subunit B (Fig. 1). By analyzing the positions of double peaks in the sequence chromatogram, different subtypes present in the same strain could be identified.
All observed chromatograms with two different toxins corresponded
to the superimposition of two known sequences; if previously
unknown sequences are present in a strain harboring two different
toxin variants, further confirmatory analyses may be required.
Construction of alignments and phylogenetic trees was performed
by DNAStar software (DNAStar Inc., Madison, WI).
This partial sequencing of the stxAB2 operon offers an easy and specific subtyping method for the Stx2 toxins. Based on the 159 amino acids, 12 different variants were identified in the Danish cohort (Fig. 1 and 2), named by subtype (nomenclature according to reference 20), O group, and strain name. Nine of these were already present in GenBank, and among these, two were for the first time found in humans (Stx2c-O157-FLY16 and Stx2g-Out-S-8).
From 1 January 1997 to 28 October 2003, the Danish National
STEC cohort contained 272 strains positive for the
stx2 gene.
Of these, 17 could not be recovered from the archives or did
not grow and the resulting 255 strains (of which 39 contained
two different toxins) were subtyped by the present method (Table
1). Fifty-two patients (20%) reported being infected during
foreign travel. Clinical data concerning HUS were available
for 241 patients, and among these patients, 20 (8.3%) developed
HUS. Clinical data concerning BD were available for 199 patients,
of which 90 (45%) had BD. Eighteen of the 20 HUS cases, but
only 40% of all cases, were from children 7 years of age or
below. All 20 HUS cases were associated with subtype Stx2 and/or
Stx2c, i.e., 19 HUS cases were associated with subtype Stx2
(Stx2-O157-EDL933 or Stx2-O48-94C) either alone (11 cases) or
in combination with variant Stx2c-O157-FLY16 (8 cases). One
strain associated with HUS was found to contain variant Stx2c-O157-FLY16
alone. Subtypes Stx2 (Stx2-O157-EDL933 and Stx2-O48-94C) and
Stx2c (Stx2c-O157-FLY16) accounted for the majority of cases
(83%) associated with BD. O157 was by far the most common O
group, accounting for 109 (42.7%) of 255 Stx2-positive strains,
and was associated with 12 HUS cases. All O157 strains from
patients with HUS were
stx1 negative and
eae positive. To calculate
adjusted odds ratios (ORs), multivariate logistic regression
analysis was performed using SAS version 9.1 (Cary, NC). The
crude and adjusted ORs for the association between HUS and subtypes
Stx2 and Stx2c and age are shown in Table
2.
eae was strongly
associated with HUS but could not be included in the model,
since this gene was identified in isolates from all 20 HUS cases.
As expected (
7), there was no association between HUS and individual
O groups, including O group O157 (crude OR, 2.18; 95% confidence
interval [CI], 0.86 to 5.56), in this data set of exclusively
stx2-positive isolates. Subtype Stx2 was strongly associated
with HUS in both the crude and the adjusted analysis, while
subtype Stx2c was associated only in the adjusted analysis.
Comparable results were found when the analysis was restricted
to the 63%
eae-positive strains (not shown). Our results do
not allow conclusions about a causal mechanism but strongly
suggest that the
stx2 and the
stx2c genes, as opposed to other
stx2 genes, are associated with development of HUS. Because
stx2c (i.e., toxin type Stx2c-O157-FLY16) was present at the
same time as subtype
stx2 in eight out of nine isolates from
HUS patients, it is not clear from our data if
stx2c can contribute
to the development of HUS on its own or merely assists subtype
stx2. It may also be speculated that the one strain associated
with HUS containing
stx2c alone has lost a bacteriophage carrying
an
stx2 gene.
View this table:
[in this window]
[in a new window]
|
TABLE 1. Stx2 subtype distribution among 255 strains from the Danish STEC cohort, listed with the clinical outcomes for HUS and BD
|
Subtype Stx2c appeared to consist of two separate groups of
toxins. The amino acid sequences of toxin variants Stx2c-O118-EH250
and Stx2c-O111-PH were divergent from those of the two other
Stx2c variants. Furthermore, they were found only in
eae-negative
strains and never in strains from HUS cases. We therefore would
suggest the introduction of a distinct nomenclature for these
subtypes, which we propose to designate subtype
stx2b.
Nucleotide sequence accession numbers.
Three sequences, Stx2d-O73-C165-02, Stx2c-O157-C394-03, and Stx2d-O8-C466-01B, were new. They were subjected to full gene sequencing and deposited in GenBank under accession numbers DQ059012, DQ235774, and DQ235775, respectively.

ACKNOWLEDGMENTS
We thank Joan Nevermann Jensen for technical assistance and
Karen A. Krogfelt for critical revision of the manuscript.

FOOTNOTES
* Corresponding author. Mailing address: Department of Bacteriology, Mycology and Parasitology, The National Reference Laboratory for Enteropathogenic Bacteria, Unit of Gastrointestinal Infections, Statens Serum Institut, Artillerivej 5, Building 37B, 2300 Copenhagen S, Denmark. Phone: 45 3268 3648. Fax: 45 3268 8130. E-mail:
SPN{at}ssi.dk 
Published ahead of print on 19 April 2007. 

REFERENCES
1 - Asakura, H., S. Makino, H. Kobori, M. Watarai, T. Shirahata, T. Ikeda, and K. Takeshi. 2001. Phylogenetic diversity and similarity of active sites of Shiga toxin (stx) in Shiga toxin-producing Escherichia coli (STEC) isolates from humans and animals. Epidemiol. Infect. 127:27-36.[CrossRef][Medline]
2 - Bastian, S. N., I. Carle, and F. Grimont. 1998. Comparison of 14 PCR systems for the detection and subtyping of stx genes in Shiga-toxin-producing Escherichia coli. Res. Microbiol. 149:457-472.[Medline]
3 - Bertin, Y., K. Boukhors, N. Pradel, V. Livrelli, and C. Martin. 2001. Stx2 subtyping of Shiga toxin-producing Escherichia coli isolated from cattle in France: detection of a new Stx2 subtype and correlation with additional virulence factors. J. Clin. Microbiol. 39:3060-3065.[Abstract/Free Full Text]
4 - Boerlin, P., S. A. McEwen, F. Boerlin-Petzold, J. B. Wilson, R. P. Johnson, and C. L. Gyles. 1999. Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J. Clin. Microbiol. 37:497-503.[Abstract/Free Full Text]
5 - Caprioli, A., I. Luzzi, A. Gianviti, H. Russmann, and H. Karch. 1995. Pheno-genotyping of verotoxin 2 (VT2)-producing Escherichia coli causing haemorrhagic colitis and haemolytic uraemic syndrome by direct analysis of patients stools. J. Med. Microbiol. 43:348-353.[Abstract/Free Full Text]
6 - Eklund, M., K. Leino, and A. Siitonen. 2002. Clinical Escherichia coli strains carrying stx genes: stx variants and stx-positive virulence profiles. J. Clin. Microbiol. 40:4585-4593.[Abstract/Free Full Text]
7 - Ethelberg, S., K. E. Olsen, F. Scheutz, C. Jensen, P. Schiellerup, J. Engberg, A. M. Petersen, B. Olesen, P. Gerner-Smidt, and K. Molbak. 2004. Virulence factors for hemolytic uremic syndrome, Denmark. Emerg. Infect. Dis. 10:842-847.[Medline]
8 - Friedrich, A. W., M. Bielaszewska, W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84.[CrossRef][Medline]
9 - Ito, H., A. Terai, H. Kurazono, Y. Takeda, and M. Nishibuchi. 1990. Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb. Pathog. 8:47-60.[CrossRef][Medline]
10 - Jelacic, J. K., T. Damrow, G. S. Chen, S. Jelacic, M. Bielaszewska, M. Ciol, H. M. Carvalho, A. R. Melton-Celsa, A. D. O'Brien, and P. I. Tarr. 2003. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J. Infect. Dis. 188:719-729.[CrossRef][Medline]
11 - Jenkins, C., G. A. Willshaw, J. Evans, T. Cheasty, H. Chart, D. J. Shaw, G. Dougan, G. Frankel, and H. R. Smith. 2003. Subtyping of virulence genes in verocytotoxin-producing Escherichia coli (VTEC) other than serogroup O157 associated with disease in the United Kingdom. J. Med. Microbiol. 52:941-947.[Abstract/Free Full Text]
12 - Jerse, A. E., J. Yu, B. D. Tall, and J. B. Kaper. 1990. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc. Natl. Acad. Sci. USA 87:7839-7843.[Abstract/Free Full Text]
13 - Lindgren, S. W., A. R. Melton, and A. D. O'Brien. 1993. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect. Immun. 61:3832-3842.[Abstract/Free Full Text]
14 - Nataro, J. P., and J. B. Kaper. 1998. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11:142-201.[Abstract/Free Full Text]
15 - Piérard, D., G. Muyldermans, L. Moriau, D. Stevens, and S. Lauwers. 1998. Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J. Clin. Microbiol. 36:3317-3322.[Abstract/Free Full Text]
16 - Pradel, N., K. Boukhors, Y. Bertin, C. Forestier, C. Martin, and V. Livrelli. 2001. Heterogeneity of Shiga toxin-producing Escherichia coli strains isolated from hemolytic-uremic syndrome patients, cattle, and food samples in central France. Appl. Environ. Microbiol. 67:2460-2468.[Abstract/Free Full Text]
17 - Roldgaard, B. B., F. Scheutz, J. Boel, S. Aabo, A. C. Schultz, T. Cheasty, E. M. Nielsen, K. E. Olsen, and B. B. Christensen. 2004. VTEC O157 subtypes associated with the most severe clinical symptoms in humans constitute a minor part of VTEC O157 isolates from Danish cattle. Int. J. Med. Microbiol. 294:255-259.[CrossRef][Medline]
18 - Russmann, H., E. Kothe, H. Schmidt, S. Franke, D. Harmsen, A. Caprioli, and H. Karch. 1995. Genotyping of Shiga-like toxin genes in non-O157 Escherichia coli strains associated with haemolytic uraemic syndrome. J. Med. Microbiol. 42:404-410.[Abstract/Free Full Text]
19 - Russmann, H., H. Schmidt, J. Heesemann, A. Caprioli, and H. Karch. 1994. Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J. Med. Microbiol. 40:338-343.[Abstract/Free Full Text]
20 - Scheutz, F., and N. A. Strockbine. 2005. Escherichia, p. 607-624. In G. M. Garrity, D. J. Brenner, N. R. Krieg, and J. T. Staley (ed.), Bergey's manual of systematic bacteriology. Springer, New York, NY.
21 - Thomas, A., H. R. Smith, G. A. Willshaw, and B. Rowe. 1991. Nonradioactively labelled polynucleotide and oligonucleotide DNA probes, for selectively detecting Escherichia coli strains producing Vero cytotoxins VT1, VT2 and VT2 variant. Mol. Cell. Probes 5:129-135.[CrossRef][Medline]
22 - Tyler, S. D., W. M. Johnson, H. Lior, G. Wang, and K. R. Rozee. 1991. Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis. J. Clin. Microbiol. 29:1339-1343.[Abstract/Free Full Text]
23 - Willshaw, G. A., H. R. Smith, S. M. Scotland, and B. Rowe. 1985. Cloning of genes determining the production of vero cytotoxin by Escherichia coli. J. Gen. Microbiol. 131:3047-3053.[Abstract/Free Full Text]
Journal of Clinical Microbiology, June 2007, p. 2020-2024, Vol. 45, No. 6
0095-1137/07/$08.00+0 doi:10.1128/JCM.02591-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Grys, T. E., Sloan, L. M., Rosenblatt, J. E., Patel, R.
(2009). Rapid and Sensitive Detection of Shiga Toxin-Producing Escherichia coli from Nonenriched Stool Specimens by Real-Time PCR in Comparison to Enzyme Immunoassay and Culture. J. Clin. Microbiol.
47: 2008-2012
[Abstract]
[Full Text]
-
Pedersen, M. G., Hansen, C., Riise, E., Persson, S., Olsen, K. E. P.
(2008). Subtype-Specific Suppression of Shiga Toxin 2 Released from Escherichia coli upon Exposure to Protein Synthesis Inhibitors. J. Clin. Microbiol.
46: 2987-2991
[Abstract]
[Full Text]
-
Beutin, L., Kruger, U., Krause, G., Miko, A., Martin, A., Strauch, E.
(2008). Evaluation of Major Types of Shiga Toxin 2e-Producing Escherichia coli Bacteria Present in Food, Pigs, and the Environment as Potential Pathogens for Humans. Appl. Environ. Microbiol.
74: 4806-4816
[Abstract]
[Full Text]
-
Manning, S. D., Motiwala, A. S., Springman, A. C., Qi, W., Lacher, D. W., Ouellette, L. M., Mladonicky, J. M., Somsel, P., Rudrik, J. T., Dietrich, S. E., Zhang, W., Swaminathan, B., Alland, D., Whittam, T. S.
(2008). From the Cover: Variation in virulence among clades of Escherichia coli O157:H7 associated with disease outbreaks. Proc. Natl. Acad. Sci. USA
105: 4868-4873
[Abstract]
[Full Text]
-
Gilmour, M. W., Tabor, H., Wang, G., Clark, C. G., Tracz, D. M., Olson, A. B., Mascarenhas, M., Karmali, M. A., Mailman, T., Ng, L.-K.
(2007). Isolation and Genetic Characterization of a Coinfection of Non-O157 Shiga Toxin-Producing Escherichia coli. J. Clin. Microbiol.
45: 3771-3773
[Abstract]
[Full Text]